SEC Form 4 · accession 0001012975-18-000023
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mitchel Sayare
Director
Period of report
Dec 29, 2017
Accepted (ET)
Jan 3, 2018 · 4:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001F1,F2 | Dec 29, 2017 | P | 5,100 | $1.9535 | A | 32,650 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $1.91 to $1.98 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price.
- F2The shares of Common Stock are owned directly by the Mitchel Sayare 2010 Trust. The Reporting Person, as sole trustee of the Mitchel Sayare 2010 Trust, may be deemed to be the beneficial owner of the securities held by the Mitchel Sayare 2010 Trust. The Reporting Person disclaims beneficial ownership of the securities held by the Mitchel Sayare 2010 Trust except to the extent of his pecuniary interest therein.